Health service utilisation for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine programme introduction: A retrospective longitudinal population-based study

BMJ Open

Volumn 6, Issue 3, 2016, Pages

  Guerra, Fiona M ^a   Rosella, Laura C ^a,b,c   Dunn, Sheila ^d,e   Wilson, Sarah E ^a,b,c   Chen, Cynthia ^a   Deeks, Shelley L ^a,b  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AMBULATORY CARE; ARTICLE; CANADA; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; FEMALE; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; ICD-10; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROXY; RETROSPECTIVE STUDY; AGE DISTRIBUTION; AGED; CONDYLOMATA ACUMINATA; FACTUAL DATABASE; INCIDENCE; MIDDLE AGED; ONTARIO; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; SEX RATIO; STATISTICS AND NUMERICAL DATA; VACCINATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CONDYLOMATA ACUMINATA; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OFFICE VISITS; ONTARIO; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; VACCINATION; YOUNG ADULT;

EID: 84962572490     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009914     Document Type: Article

References (24)

1. Winer, RL, Lee, SK, Hughes, JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
2. Freitas AC, Mariz FC, Silva MA, et al. Human papillomavirus vertical transmission: review of current data. Clin Infect Dis 2013;56:1451-6.
3. Nyitray AG, Iannacone MR. The epidemiology of human papillomaviruses. Curr Probl Dermatol 2014;45:75-91.
4. Muñoz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
5. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009;85:111-15.
6. Wang KL, Jeng CJ, Yang YC, et al. The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions. J Psychosom Obstet Gynaecol 2010;31:16-23.
7. Drolet M, Brisson M, Maunsell E, et al. The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis 2011;38:949-56.
8. Lynde C, Vender R, Bourcier M, et al. Clinical features of external genital warts. J Cutan Med Surg 2013;17(Suppl 2):S55-60.
9. Richards S. An overview of genital warts. Nurs Stand 2014;28:46-50.
10. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008;198: 827-35.
11. Insinga RP, Dasbach EJ, Elbasha EH, et al. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16:709-15.
12. Stone KM. Human papillomavirus infection and genital warts: update on epidemiology and treatment. Clin Infect Dis 1995;20(Suppl 1): S91-7.
13. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8.
14. The Canadian Guidelines on Sexually Transmitted Infections Treatment. http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/ index-eng.php (accessed Jul 2015).
15. Hariri S, Markowitz LE, Dunne EF, et al. Population impact of HPV vaccines: summary of early evidence. J Adolesc Health 2013;53:679-82.
16. Garland SM. The Australian experience with the human papillomavirus vaccine. Clin Ther 2014;36:17-23.
17. Kliewer EV, Demers AA, Elliott L, et al. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 2009;36:380-6.
18. Steben M, Ouhoummane N, Rodier C, et al. Temporal trends in genital warts among individuals covered by the public prescription drug insurance plan in the province of Quebec, Canada, from 1998 to 2007. J Low Genit Tract Dis 2013;17:147-53.
19. Chan BT, Schultz SE. Supply and utilization of general practitioner and family physician services in Ontario. Institute for Clinical Evaluative Sciences. Toronto, ON: Institute for Clinical Evaluative Sciences, 2005. http://www.ices.on.ca/Publications/Atlases-and-Reports/2005/Supply-and-utilization (accessed Jul 2015).
20. Smith LM, Strumpf EC, Kaufman JS, et al. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics 2015;135:e1131-40.
21. Camenga, DR, Dunne, EF, Desai, MM, et al. Incidence of Genital Warts in Adolescents and Young Adults in an Integrated Health Care Delivery System in the United States Before Human Papillomavirus Vaccine Recommendations. Sexually Transm Dis 2013;40:534-8.
22. Mikolajczyk RT, Kraut AA, Horn J, et al. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis 2013;40:28-31.
23. Xi LF, Koutsky LA. Epidemiology of genital human papillomavirus infections. Bulletin de l'Institut Pasteur 1997;95:161-78.
24. Brackbill RM, Sternberg MR, Fishbein M. Where do people go for treatment of sexually transmitted diseases? Fam Plann Perspect 1999;31:10-15.